Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics is compelling because Lumvoa’s first commercial quarter delivered $24.7M in net product revenue and over 100 treated patients, far above expectations, indicating true patient-driven demand rather than inventory stocking. The launch also showed strong early market access, with coverage at 30% of covered lives, 95% physician engagement since August, and a permanent J-code effective January 1, 2027 that should improve reimbursement frictions. Fundamentally, the company combines a differentiated IGF-1R franchise with veligrotug’s best-in-class potential, Elegrobart’s at-home subcutaneous expansion path, and $955.2M in cash to support operations through profitability.

Viridian Therapeutics is vulnerable to a material downside scenario because its valuation appears heavily tied to veligrotug, the company’s most advanced IV anti-IGF-1R program for thyroid eye disease, and any setback on efficacy or safety could sharply impair investor confidence. If veligrotug fails to gain approval for TED, the market could assign little to no meaningful pipeline value, leaving the stock to trade much closer to the company’s net cash position and implying only about $14 per share under that scenario. This concentration risk, combined with the binary nature of clinical and regulatory outcomes in a single lead asset, supports a negative outlook on the fundamentals.